Therefore, our findings suggest the use of drugs designed to inhibit either the complement cascade or the NLRP3/ASC/caspase-1/4/5 molecules as a potential new therapeutic approach to treat TB-IRIS. The gene discussed is CASP1; the disease is tuberculosis.